Clinical testing for pathogenic variants in the BRCA1 and BRCA2 (ie, BRCA1/2) gene became available in 1995.4 Risk-assessment strategies, based on personal and family history cancer thresholds, have been built, validated, and incorporated into clinical testing guidelines. This evidence concerns the gene BRCA1 and cancer.